Sesen Bio, Inc.

Sesen Bio, Inc. (SESN), relating to its proposed merger with Carisma Therapeutics Inc. Under the terms of the agreement, SESN shareholders are expected to own approximately 41.7% of the combined company.

To receive more information regarding the investigation of Sesen Bio, Inc. please fill out the form below.